An NF2 -wildtype malignant meningioma cell line for basic and translational science

Verdict. There are few good cellular models, especially of high grade/malignant meningiomas, to use to identify new therapeutic agents and treatment regimens. It intersects mitochondrial stress/dysfunction themes (mtDNA; cancer).

What the authors report

Background: : Meningiomas are the most common primary nervous system neoplasm in adults. The widely available, partially characterized, NF2 -wildtype ( NF2wt ) Grade 3 malignant meningioma cell line IOMM-Lee can help meet this need.

Key results stated in the abstract include the following. There are few good cellular models, especially of high grade/malignant meningiomas, to use to identify new therapeutic agents and treatment regimens. Methods: : We generated new data to better characterize IOMM-Lee genomic and mtDNA variants, proliferation rate and colony-forming efficiency and sensitivity to ionizing radiation as a function of ATM kinase activity. Importance of the Study : We provide new data to better characterize IOMM-Lee, the most widely used cell line model of human Grade 3 malignant meningioma.

Why it matters for mitochondrial biology

Within mitochondrial research, this work maps primarily to mtDNA, cancer, therapeutics, computational. It is relevant to mitochondrial dysfunction discourse because the abstract invokes mtDNA, cancer. That does not by itself establish a validated disease mechanism; it indicates thematic proximity. Because a therapeutic or interventional angle is present, the piece is of interest for mitochondrial-targeted drug hypothesis generation—subject to full-text validation of endpoints and safety context. Server: biorxiv. Posted 2026-08-11. Synthesis confidence is bounded by abstract completeness.

Study design (abstract-level)

There are few good cellular models, especially of high grade/malignant meningiomas, to use to identify new therapeutic agents and treatment regimens. The widely available, partially characterized, NF2 -wildtype ( NF2wt ) Grade 3 malignant meningioma cell line IOMM-Lee can help meet this need. Results: : Exome sequencing confirmed that IOMM-Lee is NF2wt, and contains a pathogenic TERT -promoter (c.-124C>T) variant.

Principal findings

1. There are few good cellular models, especially of high grade/malignant meningiomas, to use to identify new therapeutic agents and treatment regimens.
2. Methods: : We generated new data to better characterize IOMM-Lee genomic and mtDNA variants, proliferation rate and colony-forming efficiency and sensitivity to ionizing radiation as a function of ATM kinase activity.
3. Importance of the Study : We provide new data to better characterize IOMM-Lee, the most widely used cell line model of human Grade 3 malignant meningioma.
4. These data identify and characterize IOMM-Lee genomic alterations and mtDNA variants; quantify growth kinetics and ionizing radiation sensitivity; and identify multiple mechanistically distinct, clinical use drugs with nanomolar IC50 values, high drug sensitivity prediction scores and potential as meningioma systemic therapies.
5. Our data more clearly locate IOMM-Lee in the landscape of genomically-defined meningiomas, and will aid better use of this experimentally tractable cell line model to understand meningioma biology and identify more effective malignant meningioma therapies and treatment regimens.

Limitations of this brief

• This Mitos brief is an abstract-level synthesis of a preprint; it is not peer review and not a substitute for reading the full paper.
• Preprint status: findings may change with revision or journal review.
• Effect sizes, n numbers, statistics, and full experimental controls are typically incomplete at abstract resolution.
• Primary source: biorxiv DOI 10.64898/2026.08.10.744059 (posted 2026-08-11).

Open scientific questions

• Which specific experimental panels in the full paper establish the strongest causal claim, and how robust are the controls?
• What dose, timing, and off-target profile would be required to take the intervention seriously as a therapeutic hypothesis?
• Are mtDNA copy-number or mutation effects measured directly, or inferred from downstream phenotypes?
• How do these findings sit relative to prior literature on the same pathway—replication, contradiction, or incremental extension?

Bottom line

For mitochondrial biologists focused on mtDNA, cancer, therapeutics, this preprint is worth full-text review if the topic matches your program. Abstract-level takeaway: There are few good cellular models, especially of high grade/malignant meningiomas, to use to identify new therapeutic agents and treatment regimens. Confirm methods, effect sizes, and controls in the full PDF before citing the result as established.

Bibliographic record

Abstract-based editorial synthesis by Mitos. Not peer review.